The Precision CAD Trial

Use of Biomarker Risk Score to Optimize Therapy in Patients With Coronary Artery Disease: The Precision CAD Trial

People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complications from CAD. The purpose of this study is to see if a customized treatment based on biomarkers will reduce the biomarker levels and lead to lower risk of complications from CAD.

Study Overview

• Status: Recruiting
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Other: Medical/Behavioral therapy; Other: Standard of Care; Other: Registry

Detailed Description

People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complications from CAD. The purpose of this study is to see if a customized treatment based on biomarkers will reduce the biomarker levels and lead to lower risk of complications from CAD.

Participants with high biomarker levels will be randomly assigned (like flipping a coin) to either the treatment group or usual care. Both groups will have physical exams, blood tests, and answer questionnaires. Participants in the treatment group will have their medications adjusted based on their biomarker levels. They will also be asked to make lifestyle changes like diet, exercise, and quitting smoking. Participants in the usual care group will receive the standard of care prescribed by their doctor.

This study will take place in research rooms at Emory University Hospital and the Woodruff Memorial Research Building.

Participants will be paid for being in the study.

Participants will be recruited from Emory Healthcare outpatient cardiology clinics and cath labs. Participants will be identified through the medical record and by their doctors. Written consent will be obtained from Participants before they can join the study.

Study data and blood samples will be collected and banked for possible research in the future. These may also be shared with other researchers including researchers outside of Emory.

This study will advance scientific knowledge and benefit human health by giving us more treatment options for CAD.

• Study Type: Interventional
• Enrollment (Estimated): 450
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Joey Freshwater; Phone Number: 404-712-6635; Email: joey.freshwater@emory.edu

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Recruiting
      • Emory University Hospital Midtown
      • Contact: Joey Freshwater
    • Atlanta, Georgia, United States, 30342
      • Recruiting
      • Emory Saint Joseph's Hospital
      • Contact: Joey Freshwater
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Emory University Hospital
      • Contact: Joey Freshwater
    • Atlanta, Georgia, United States, 30097
      • Recruiting
      • Emory Johns Creek Hospiatl
      • Contact: Joey Freshwater
    • Atlanta, Georgia, United States, 30324
      • Recruiting
      • The Emory Clinic
      • Contact: Joey Freshwater

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Individuals aged 21-90 years with stable CAD.
• Patients with any amount of atherosclerosis via coronary angiogram or coronary computed tomography angiography (CCTA).
• Patients undergoing revascularization therapy or recent acute coronary syndrome (ACS) will be eligible for recruitment and will be recruited at least 4 weeks after admission for an ACS or percutaneous intervention and 3 months after coronary bypass graft surgery.
• Patients with CAC levels ≥ 400

Exclusion Criteria:

• Planned revascularization,
• New York Heart Association class III or IV heart failure symptoms,
• LVEF <40%,
• eGFR<45,
• Pregnancy, congenital heart disease, severe symptomatic valvular heart disease, active malignancy and cardiac transplant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Optimization Group; Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C<70 mg/dL, hemoglobin A1c <7%, blood pressure <130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index <30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.	Other: Medical/Behavioral therapy; Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.; Overweight/Obese: Advise calorie reduction, dietician consultation.; Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.; High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of <55mg/dl in diabetes; Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.; Diabetes management: HbA1c goal 6.5%
Active Comparator: Usual Care Group; Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.	Other: Standard of Care; Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
Other: Registry Group; Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.	Other: Registry; Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in plasma levels of hsCRP	Blood will be drawn for measurement of plasma levels of hsCRP to compare the optimization group and the usual care group.	Baseline, 1 year post intervention
Change in plasma levels of hs-cTnI	Blood will be drawn for measurement of plasma levels of hs-cTnI to compare the optimization group and the usual care group.	Baseline, 1 year post intervention
Change in plasma levels of BNP	Blood will be drawn for measurement of plasma levels of BNP to compare the optimization group and the usual care group.	Baseline, 1 year post intervention
Change in plasma levels of suPAR	Blood will be drawn for measurement of plasma levels of suPAR to compare the optimization group and the usual care group.	Baseline, 1 year post intervention
Change in Biomarker Risk Score (BRS)	The BRS score is a simple and manual observation of 4 biomarker results above a predetermined cutpoint that are run on FDA cleared and or CE marked platforms. The BRS is calculated using levels of the 4 biomarkers. Biomarker levels will be considered abnormal if hsCRP is >3 mg/L, suPAR (pg/mL) >2863 (males) and >4063 (women), hs-TnI (pg/mL)> 6.3 (men), >5.5 (women), and BNP (pg/mL) >122 (men), >184.1 (women). The BRS ranges from 0 to 4 based on the number of biomarkers that are elevated above these cut off values. Higher score correlates with worse outcome.	Baseline, 1 year post intervention
Change in composite complications	Difference in rates of composite of CV death/MI/ heart failure hospitalizations, stroke/ revascularization between optimization group, usual care group and registry group.	Baseline, 1,3,6,9 months post intervention and 1,2,3,5 years post intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in plasma levels of hsCRP	Blood will be drawn for measurement of plasma levels of hsCRP to compare the optimization group and the usual care group.	Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention
Change in plasma levels of hs-cTnI	Blood will be drawn for measurement of plasma levels of hs-cTnI to compare the optimization group and the usual care group.	Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention
Change in plasma levels of BNP	Blood will be drawn for measurement of plasma levels of BNP to compare the optimization group and the usual care group.	Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention
Change in plasma levels of suPAR	Blood will be drawn for measurement of plasma levels of suPAR to compare the optimization group and the usual care group.	Baseline, 1, 3, 6, 9 months post intervention and 2, 3, 5 years post intervention
All cause death	All cause death at 5 years in the optimization group compared to usual care group.	5 years post intervention

Collaborators and Investigators

• Sponsor: Emory University
• Investigators: Principal Investigator: Arshed Quyyumi, MD, Emory University

Study record dates

Study Major Dates

• Study Start (Actual): October 19, 2022
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: February 11, 2021
• First Submitted That Met QC Criteria: February 11, 2021
• First Posted (Actual): February 16, 2021

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 25, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Coronary Artery Disease; Biomarkers
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
• Other Study ID Numbers: STUDY00001179

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No